Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Two-year, Phase 4, Open-label, Single-arm Treatment Study to Evaluate the Long-term Effect of Dupilumab on Skin Barrier Function in Pediatric Participants (≥6 to <15 Years of Age) With Moderate-to-severe Atopic Dermatitis

NCT05983068 is registered in ClinicalTrials.gov with Sanofi as lead sponsor.

NCT NCT05983068
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05983068 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Two-year, Phase 4, Open-label, Single-arm Treatment Study to Evaluate the Long-term Effect of Dupilumab on Skin Barrier Function in Pediatric Participants (≥6 to <15 Years of Age) With Moderate-to-severe Atopic Dermatitis
Lead sponsor
Sanofi
Phase
Phase 4
Overall status
Active, not recruiting
Start date
February 22, 2024
Completion date
May 19, 2027
Enrollment
48 (estimated)
Sites
4

Conditions

As the registry lists them; a condition with its own page is linked.

dermatitis atopic